Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

Stock factor profile

PPLPHARMA

PPLPHARMA · Healthcare · Pharmaceuticals & Biotechnology

Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 6,295 full-time employees. The company went IPO on 2022-10-19. The firm has approximately 17 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.

Last price₹214.49
1 day+0.33%
1 month+7.63%
Model ratingLocked
Data as of03 Sep 2026

Performance

Price history

Equity review factors

Factor profile

Factor scores are part of the Wright portfolio review.

Run your free portfolio review

Fundamental snapshot

Fundamentals at a glance

Market cap27406
P/E ratio-83.0
Factor betaLocked
VolatilityLocked
Model scoreLocked
Screen passLocked

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.